NYSE:PFEPharmaceuticals
Will PADCEV–Keytruda Trial Success in Bladder Cancer Change Pfizer's (PFE) Pipeline-Driven Narrative?
Astellas Pharma and Pfizer recently reported that their Phase 3 EV-304 trial of PADCEV plus Keytruda in muscle-invasive bladder cancer met key efficacy and safety endpoints versus standard cisplatin-based chemotherapy.
This oncology success arrives just as Pfizer is guiding for softer 2026 revenues and earnings, underlining management’s reliance on pipeline progress to offset COVID-19 and patent headwinds.
We’ll now examine how Pfizer’s cautious 2026 guidance, set against this positive...